ERBB2 and peritoneal carcinoma: In a phase 2 clinical trial of trastuzumab in 41 patients with recurrent or refractory ovarian or primary peritoneal carcinoma and HER2 expression scores of 2 or 3, the overall objective response rate was 7.3% (one complete response and two partial responses) [48].